Jefferies Group reaffirmed their buy rating on shares of GlaxoSmithKline PLC (NYSE:GSK) in a research report sent to investors on Wednesday.

Several other research analysts have also weighed in on GSK. Citigroup Inc. reaffirmed a buy rating on shares of GlaxoSmithKline PLC in a research note on Thursday, June 23rd. Beaufort Securities reaffirmed a buy rating on shares of GlaxoSmithKline PLC in a research note on Tuesday, June 21st. HSBC reaffirmed a buy rating on shares of GlaxoSmithKline PLC in a research note on Monday, September 12th. Cowen and Company lowered shares of GlaxoSmithKline PLC from an outperform rating to a market perform rating in a research note on Thursday, May 26th. Finally, Shore Capital reissued a hold rating on shares of GlaxoSmithKline PLC in a research note on Tuesday, June 21st. Two analysts have rated the stock with a sell rating, eleven have issued a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the company. The stock has a consensus rating of Hold and a consensus price target of $47.19.

Shares of GlaxoSmithKline PLC (NYSE:GSK) opened at 43.30 on Wednesday. The stock has a market cap of $105.24 billion, a P/E ratio of 2706.25 and a beta of 0.85. The firm’s 50-day moving average is $43.97 and its 200 day moving average is $42.57. GlaxoSmithKline PLC has a 52-week low of $37.24 and a 52-week high of $45.58.

The firm also recently announced a dividend, which will be paid on Thursday, October 13th. Stockholders of record on Friday, August 12th will be issued a $0.494 dividend. The ex-dividend date is Wednesday, August 10th. GlaxoSmithKline PLC’s payout ratio is 6,600.00%.

Several institutional investors have recently made changes to their positions in GSK. Meyer Handelman Co. boosted its position in shares of GlaxoSmithKline PLC by 0.7% in the fourth quarter. Meyer Handelman Co. now owns 59,853 shares of the pharmaceutical company’s stock worth $2,415,000 after buying an additional 400 shares during the last quarter. Stifel Financial Corp boosted its position in shares of GlaxoSmithKline PLC by 0.8% in the fourth quarter. Stifel Financial Corp now owns 1,159,887 shares of the pharmaceutical company’s stock worth $22,479,000 after buying an additional 9,028 shares during the last quarter. Norges Bank acquired a new position in shares of GlaxoSmithKline PLC during the fourth quarter worth approximately $20,124,000. Iowa State Bank boosted its position in shares of GlaxoSmithKline PLC by 1.8% in the first quarter. Iowa State Bank now owns 40,551 shares of the pharmaceutical company’s stock worth $1,644,000 after buying an additional 715 shares during the last quarter. Finally, CENTRAL TRUST Co acquired a new position in shares of GlaxoSmithKline PLC during the first quarter worth approximately $1,653,000. 9.03% of the stock is currently owned by institutional investors and hedge funds.

About GlaxoSmithKline PLC

GlaxoSmithKline plc (GSK) is a healthcare company. The Company is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products. The Company’s segments include Pharmaceuticals, Pharmaceuticals R&D, Vaccines and Consumer Healthcare.

5 Day Chart for NYSE:GSK

Receive News & Ratings for GlaxoSmithKline PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline PLC and related companies with MarketBeat.com's FREE daily email newsletter.